iSpecimen Q3 2022 revenue $2.6M; non-COVID revenue up 26% YoY; net loss widens to $3.1M

iSpecimen Inc.

2022-Q3 EPS reported -$0.92 revenue$7,440,760

Revenue $2.6M (down 4% YoY); non-COVID revenue $2.26M (record 88% mix, up 26% YoY).
Net loss $3.1M ($0.35 per share) vs $1.6M loss ($0.22) in Q3 2021; cost of revenue up 33%.
Cash $20.7M as of Sep 30, 2022, down from $27.7M at Dec 31, 2021.
Tracy Curley appointed Interim CEO; she remains CFO and Treasurer.
Unique customer orgs 480 (+21% YoY); marketplace users ~6,500 (+32% YoY).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

iSpecimen Inc. reported three- and nine-month period ended September 30, 2022 results: revenue $2.6 million, net income $3.1 million, or $(0.35) per share, EPS $(0.35) per share.

Period: three- and nine-month period ended September 30, 2022
Revenue: $2.6 million
Net income: $3.1 million, or $(0.35) per share
EPS: $(0.35) per share
Result: reported results

Exact text from the filing

Revenue for the third quarter of 2022 was approximately $2.6 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

iSpecimen Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-115720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.